Supernus Pharmaceuticals Income After Taxes 2011-2024 | SUPN

Supernus Pharmaceuticals income after taxes from 2011 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Supernus Pharmaceuticals Annual Income After Taxes
(Millions of US $)
2023 $1
2022 $61
2021 $53
2020 $127
2019 $113
2018 $111
2017 $57
2016 $91
2015 $14
2014 $-11
2013 $-92
2012 $-46
2011 $-23
2010 $-39
Supernus Pharmaceuticals Quarterly Income After Taxes
(Millions of US $)
2024-06-30 $20
2024-03-31 $0
2023-12-31 $1
2023-09-30 $-16
2023-06-30 $-1
2023-03-31 $17
2022-12-31 $25
2022-09-30 $2
2022-06-30 $8
2022-03-31 $26
2021-12-31 $2
2021-09-30 $22
2021-06-30 $24
2021-03-31 $6
2020-12-31 $31
2020-09-30 $40
2020-06-30 $35
2020-03-31 $22
2019-12-31 $33
2019-09-30 $29
2019-06-30 $33
2019-03-31 $18
2018-12-31 $26
2018-09-30 $28
2018-06-30 $31
2018-03-31 $26
2017-12-31 $14
2017-09-30 $16
2017-06-30 $17
2017-03-31 $10
2016-12-31 $14
2016-09-30 $62
2016-06-30 $10
2016-03-31 $5
2015-12-31 $7
2015-09-30 $4
2015-06-30 $2
2015-03-31 $1
2014-12-31 $4
2014-09-30 $-2
2014-06-30 $3
2014-03-31 $-16
2013-12-31 $-22
2013-09-30 $-24
2013-06-30 $-27
2013-03-31 $-18
2012-12-31 $-14
2012-09-30 $-13
2012-06-30 $-10
2012-03-31 $-9
2011-12-31 $6
2011-09-30 $-10
2011-06-30 $-9
2011-03-31 $-10
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.022B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00